Cleveland HeartLab Inc., a leading specialty clinical laboratory and disease management company, today announced the completion of an $18.4-million Series B financing round.

The funds will support CHL’s continued rapid growth, further accelerating market adoption of its advanced approach to assessing cardiovascular disease risk using biomarkers of inflammation. This approach includes the company’s CardioMPO test for circulating myeloperoxidase, the anchor of its proprietary inflammation panel.

More details here.